Site icon Duncan Bucknell

Pharma & Biotech Global Week in Review 29 Dec 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.


Highlights this week included:

CAFC: Broad scope of statutory subject matter: Prometheus Laboratories, Inc. v. Mayo Collaborative Services (Patently-O) (Filewrapper) (Patents4Life) (Patent Docs) (Inventive Step)


Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.



Nations closer to pandemic vaccine framework, key negotiator says (IP Watch)

Differences in ratio of deaths to new cases for 6 cancer types in 14 WHO regions, with reference to income of region (KEI)

Australia: Australian Senate inquiry seeks submissions on ‘gene patent’ amendments (Patentology) (

EU: A chance to comment on the Yeda reference, but you’d better be quick (The SPC Blog)

EU: The word is out: Patenting plant breeding methods – G 02/07 and G 01/08 making patentability of breeding methods harder if not impossible (IPEG)

France: Institut Pasteur v Abbott – A new episode on the AIDS patent dispute (Kluwer Patent Blog)

Spain: Can a generic that cannot be marketed be taken into account to include the ‘reference medicament’ in the price reference system? (Kluwer Patent Blog)

US: BIO sends letter to DOJ on ‘clear and convincing evidence’ question raised in Microsoft v. i4i (Patent Docs)

US: CAFC: Broad scope of statutory subject matter: Prometheus Laboratories, Inc. v. Mayo Collaborative Services (Patently-O) (Filewrapper) (Patents4Life) (Patent Docs) (Inventive Step)

US: Lawsuit alleging infringement of canine genotyping patent raise interesting patent eligibility issues (Holman’s Biotech IP Blog)

US: Will Bessie, Porky, Puss and Poly get their meds? – FDA again seeking to restrict marketing of unapproved animal drugs (FDA Law Blog)

US: Notorious affiliate exclusion provision of PPACA repealed (FDA Law Blog)

US: Cephalon’s gambit in pay-to-delay (IPBiz)

US: Labcorp’s failed patent re-examination challenge at issue in contract dispute: Lab Corp. of Am. Holdings v Metabolite Labs (Patents Post Grant)

US: District Court Arizona: Question of whether to incur ‘substantial expenses’ for testing and clinical trials does not create substantial controversy sufficient to assert declaratory relief claim: W L Gore & Assoc. v GI Dynamics (Docket Report)

US: Correction of inventorship complaint: Salk Institute for Biological Studies v. Ferring Pharmaceuticals, Inc et al. (Patent Docs)

US: Fred Hutchinson Cancer Research Center files patent infringement complaints against MMI Genomics and Biopet Vet based on their dog breed identification services (Patent Docs)


Actonel (Risedronate) – US: Warner Chilcott files patent infringement complaint against Apotex following Para IV certification filing (Patent Docs)

Actos (Pioglitazone), Actoplus (Pioglitazone, Metformin) – US: Teva settles patent litigation with Takeda (The IP Factor)

Amlodipine – Spain: Supreme Court rules ‘Bolar provision’ may not be applied retrospectively and the provision is not simply a ‘clarification’ of the experimental use exception: Laboratorios Cinfa, S.A. v. Pfizer Ltd (Kluwer Patent Blog)

Boniva (Ibandronate) – US: Roche dodges Cobalt invalidity contention in Boniva patent suit (Patent Docs)

Boniva (Ibandronate) – US: Hoffman-La Roche files patent infringement suit against Mutual Pharmaceutical Company following Para IV certification filing (Patent Docs)

Botox (Botulinum) – EU: General Court confirms declarations of invalidity of BOTOLIST and BOTOCYL filed by Allergan: T-345/08 and T-357-08 (Class 46)

Detrol (Tolterodine) – US: Impax files for declaratory judgment of non-infringement against Pfizer following Para IV certification filing (Patent Docs)

Detrol (Tolterodine) – India: Misuse of post-grant opposition proceedings: Pfizer Health v Ranbaxy Labs/ Ltd. (Spicy IP)

Fentanyl – Germany: Supreme Court overrules Federal Patent Court’s restrictive interpretation in case of inconsistency between preamble and claim (EPLAW)

Fluvastatine – Belgium: Court of Appeal Brussels preliminarily enjoins Mylan from infringing Novartis’ patent (Kluwer Patent Blog)

Glucotrol (Glipizide) – US: Alza files patent infringement complaint against Mylan following Para IV certification filing (Patent Docs)

Hectorol (Doxercalciferol) – US: Sandoz requests 180-day exclusivity forfeiture decision for generic Hectorol (FDA Law Blog)

Metvixia (Methyl aminolevulinate) – US: CAFC: An ‘active ingredient’ of a drug must be present when the drug is administered: PhotoCure ASA v Kappos (JIPLP)

Oracea (Doxycycline) – US: Galderma files patent infringement complaint against Lupin following Para IV certification filing (Patent Docs)

Oxaliplatin – US: CAFC: Objectively ambiguous license agreement: Sanofi-Aventis v. Sandoz, Inc (IPBiz) (Patent Docs)

Plavix (Clopidogrel) – Brazil: Superior Court of Justice denies Plavix patent extension (IP tango)

Prandin (Repaglinide) – US: Novo Nordisk and Sandoz settle infringement claims in Prandin dispute (Patent Docs)

Prandin (Repaglinide) – US: Supreme Court petitioned to review Federal Circuit patent use code decision: Caraco v Novo Nordisk (FDA Law Blog)

Exit mobile version